DDInter380 DDInter1435
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Cimetidine {u} (Compound) treats {v} (Disease) obesity
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Cimetidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Cimetidine {u} (Compound) downregulates {v} (Gene) COTL1
Cimetidine {u} (Compound) causes {v} (Side Effect) Flatulence
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quinestrol
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indomethacin
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Cimetidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Cimetidine (Compound) treats obesity (Disease)
Cimetidine (Compound) binds CYP3A7-CYP3A51P (Gene)
Cimetidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Cimetidine (Compound) downregulates COTL1 (Gene)
Cimetidine (Compound) causes Flatulence (Side Effect)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib